Intersect ENT, which sells absorbable nasal implants for post-surgical sinusitis relief, raised $55 million by offering 5.0 million shares at $11, the low end of the range of $11 to $13. Intersect ENT plans to list on the NASDAQ under the symbol XENT. Intersect ENT initially filed confidentially on 5/2/2014. J.P. Morgan and Piper Jaffray acted as lead managers on the deal.
